Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

Importance Immunotherapy has been associated with improved outcomes among patients
who have received previous treatment for microsatellite instability–high (MSI-H) tumors …

Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Sequence alterations in microsatellites and an elevated mutational burden are observed in
20% of gastric cancers and associated with clinical response to anti–PD-1 antibodies …

Colorectal cancer (CRC) patients, especially those with deficient mismatch repair
(dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune …